Literature DB >> 22284418

Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis.

Aditya Murthy1, Yang Washington Shao, Swami R Narala, Sam D Molyneux, Juan Carlos Zúñiga-Pflücker, Rama Khokha.   

Abstract

Epithelial cells of mucosal tissues provide a barrier against environmental stress, and keratinocytes are key decision makers for immune cell function in the skin. Currently, epithelial signaling networks that instruct barrier immunity remain uncharacterized. Here we have shown that keratinocyte-specific deletion of a disintegrin and metalloproteinase 17 (Adam17) triggers T helper 2 and/or T helper 17 (Th2 and/or Th17) cell-driven atopic dermatitis and myeloproliferative disease. In vivo and in vitro deficiency of ADAM17 dampened Notch signaling, increasing production of the Th2 cell-polarizing cytokine TSLP and myeloid growth factor G-CSF. Ligand-independent Notch activation was identified as a regulator of AP-1 transcriptional activity, with Notch antagonizing c-Fos recruitment to the promoters of Tslp and Csf3 (G-CSF). Further, skin inflammation was rescued and myeloproliferation ameliorated by delivery of active Notch to Adam17(-)(/-) epidermis. Our findings uncover an essential role of ADAM17 in the adult epidermis, demonstrating a gatekeeper function of the ADAM17-Notch-c-Fos triad in barrier immunity.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22284418     DOI: 10.1016/j.immuni.2012.01.005

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  51 in total

1.  ADAM17 -- gatekeeper of the skin barrier.

Authors:  Lucy Bird
Journal:  Nat Rev Immunol       Date:  2012-02-24       Impact factor: 53.106

2.  Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17.

Authors:  Juan Guinea-Viniegra; Rainer Zenz; Harald Scheuch; María Jiménez; Latifa Bakiri; Peter Petzelbauer; Erwin F Wagner
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

Review 3.  Metalloproteinases and their natural inhibitors in inflammation and immunity.

Authors:  Rama Khokha; Aditya Murthy; Ashley Weiss
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

Review 4.  Cutaneous Notch signaling in health and disease.

Authors:  Craig Nowell; Freddy Radtke
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

5.  Dysbiosis and Staphylococcus aureus Colonization Drives Inflammation in Atopic Dermatitis.

Authors:  Tetsuro Kobayashi; Martin Glatz; Keisuke Horiuchi; Hiroshi Kawasaki; Haruhiko Akiyama; Daniel H Kaplan; Heidi H Kong; Masayuki Amagai; Keisuke Nagao
Journal:  Immunity       Date:  2015-04-21       Impact factor: 31.745

Review 6.  Notch as a tumour suppressor.

Authors:  Craig S Nowell; Freddy Radtke
Journal:  Nat Rev Cancer       Date:  2017-02-03       Impact factor: 60.716

7.  Host-microbial dialogues in atopic dermatitis.

Authors:  Tetsuro Kobayashi; Keisuke Nagao
Journal:  Int Immunol       Date:  2019-07-13       Impact factor: 4.823

8.  Niche-Specific Factors Dynamically Regulate Sebaceous Gland Stem Cells in the Skin.

Authors:  Natalia A Veniaminova; Marina Grachtchouk; Owen J Doane; Jamie K Peterson; David A Quigley; Madison V Lull; Daryna V Pyrozhenko; Raji R Nair; Matthew T Patrick; Allan Balmain; Andrzej A Dlugosz; Lam C Tsoi; Sunny Y Wong
Journal:  Dev Cell       Date:  2019-09-26       Impact factor: 12.270

9.  TIMP3 controls cell fate to confer hepatocellular carcinoma resistance.

Authors:  V Defamie; O Sanchez; A Murthy; R Khokha
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

Review 10.  Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.

Authors:  Naoko Takebe; Lucio Miele; Pamela Jo Harris; Woondong Jeong; Hideaki Bando; Michael Kahn; Sherry X Yang; S Percy Ivy
Journal:  Nat Rev Clin Oncol       Date:  2015-04-07       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.